2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery …
G Hindricks, T Potpara, N Dagres, E Arbelo… - European heart …, 2021 - academic.oup.com
MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation
YNV Reddy, M Obokata, FH Verbrugge, G Lin… - Journal of the American …, 2020 - jacc.org
Background Paroxysmal and permanent atrial fibrillation (AF) are common in heart failure
with preserved ejection fraction (HFpEF). Objectives This study sought to determine the …
with preserved ejection fraction (HFpEF). Objectives This study sought to determine the …
Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models
Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest
challenges facing cardiovascular medicine today. Despite being the most common form of …
challenges facing cardiovascular medicine today. Despite being the most common form of …
Atrial Functional Mitral Regurgitation: JACC Review Topic of the Week
S Deferm, PB Bertrand, FH Verbrugge… - Journal of the American …, 2019 - jacc.org
Unlike secondary mitral regurgitation (MR) in the setting of left ventricular (LV) disease, the
occurrence of functional MR in atrial fibrillation (AF) and/or heart failure with preserved …
occurrence of functional MR in atrial fibrillation (AF) and/or heart failure with preserved …
Heart failure with preserved ejection fraction
CE Hamo, C DeJong, N Hartshorne-Evans… - Nature Reviews …, 2024 - nature.com
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart
failure cases and has a prevalence that is expected to rise with the growing ageing …
failure cases and has a prevalence that is expected to rise with the growing ageing …
Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial
Importance There is little evidence to support selection of heart rate control therapy in
patients with permanent atrial fibrillation, in particular those with coexisting heart failure …
patients with permanent atrial fibrillation, in particular those with coexisting heart failure …
Heart failure with preserved ejection fraction: from mechanisms to therapies
This review aims to provide a translational perspective on recent developments in heart
failure with preserved ejection fraction (HFpEF), linking mechanistic insights to potential …
failure with preserved ejection fraction (HFpEF), linking mechanistic insights to potential …
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced …
Background Diabetes mellitus is an important risk factor for atrial fibrillation (AF)
development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the …
development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the …